Trials / Recruiting
RecruitingNCT06776861
A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A prospective, multicenter, observational cohort study assessing the efficacy and safety of radiotherapy-sensitized immunotherapy in advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PD-1 / PD-L1 monoclonal antibody | Patients with advanced breast cancer who have already received and continue to use immunotherapy, or are planned to receive immunotherapy, and have been recommended for radiotherapy after evaluation by a multidisciplinary team (MDT) in the early stage and have completed radiotherapy, are registered and followed up in this study. |
Timeline
- Start date
- 2024-09-24
- Primary completion
- 2028-09-10
- Completion
- 2028-09-10
- First posted
- 2025-01-15
- Last updated
- 2025-01-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06776861. Inclusion in this directory is not an endorsement.